Coagulation factor replacement therapy

This page covers all Coagulation factor replacement therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Coagulation Factor VIII, Factor VIII (coagulation factor VIII), Factor VIII.

Targets

Coagulation Factor VIII · Factor VIII (coagulation factor VIII) · Factor VIII · Multiple coagulation factors (Factor VIII, Factor IX, Factor V, fibrinogen, prothrombin complex components)

Marketed (1)

• Recombinant Human Coagulation FVIII · Sinocelltech Ltd. · Hematology
  Recombinant human coagulation factor VIII replaces deficient or dysfunctional Factor VIII to restore the intrinsic coagulation pathway and enable normal blood clot formation.

Phase 3 pipeline (3)

• Factor VIII (FVIII) · Hoffmann-La Roche · Hematology
  Factor VIII is a clotting factor that replaces deficient or dysfunctional coagulation factor VIII to restore blood clotting ability in hemophilia A patients.
• human VWF/FVIII concentrate · Octapharma · Hematology
  Human VWF/FVIII concentrate replaces clotting factors in the blood to prevent or control bleeding episodes in patients with hemophilia A.
• factor concentrates · Genzyme, a Sanofi Company · Hematology
  Factor concentrates replace or supplement deficient clotting factors to restore hemostatic function in patients with bleeding disorders.

Phase 2 pipeline (1)

• Activated Prothrombin Complex Concentrate · Hoffmann-La Roche · Hematology
  Activated Prothrombin Complex Concentrate works by replacing clotting factors to help the blood to clot.